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The species-specific and the interspecies cross-reac-
tive melanoma antigenic determinants are defined by 
the monoclonal antibodies raised by syngeneic immuni-
zations. The two types of monoclonal antibodies (M562 
or M622 and M2590) were obtained by the fusion of 
P3Ul murine myeloma cell lines and spleen cells of 
C57BL/6 mice hyperimmunized with MMC-treated syn-
geneic B16 melanoma cells. The M2590 antibody rec-
ognizes the cross-species melanoma determinant com-
monly shared among at least mouse, hamster, and hu-
man, while the M562 or M622 antibody reacts with the 
mouse (BI6) melanoma antigenic determinant. The im-
munochemical and physiochemical characteristics of the 
melanoma antigens on SDS-P AGE analyses show that 
these two characteristic determinants are present on the 
same molecule (molecular weight of 31,000) of a glyco-
protein. Furthermore, the interspecies cross-reactive 
melanoma antigenic determinants are possibly com-
posed of the sugar moiety, whereas the species-specific 
determinants seem to be proteinaceous in nature. 
Melanoma cells express antigens that are able to be recog-
nized by the immune systems of the syngeneic or autologous 
hosts [1- 4]. Generally, such antigens are designated as mela-
noma-specific antigens. Among melanoma antigens, we have 
demonstrated the interspecies cross-reactive antigenic deter-
minants detected by murine cytotoxic T -Iymphocytes specific 
for syngeneic melanoma cells [5] . C57BL/6 cytotoxic T cells 
induced by syngeneic B16 melanomas killed human as well as 
mouse melanoma cells in an antigen-specific manner. There-
fore, it is suggested that melanoma cells possess tumor antigenic 
determinants widely shared in mammalian species. From these 
assumptions it can be expected that the syngeneic immuniza-
tion of C57BL/6 mice with B16 melanoma cells induces the 
production of antibodies reactive with interspecies cross-reac-
tive determinants on melanoma antigens. Particularly, the 
syngeneic monoclonal antibodies overcome the complexicity of 
antibodies to tumor-associated antigens generated by allogeneic 
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or xenogeneic immunizations. In this respect, syngeneic mon-
oclonal anti-tumor antibodies can be expected to be truly 
dependable and useful tools for characterizing the biochemical 
nature and immunologic significance of tumor-associated an-
tigens. 
In this communication we will describe the derivation of two 
types of hybridomas producing anti -melanoma antibodies that 
were developed by syngeneic immunizations. One is directed to 
the interspecies cross-reactive determinant present on mouse, 
hamster, and human melanoma cells, and the other recognizes 
only the mouse melanoma antigen. By using these antibodies, 
the biochemical and physicochemical properties of the mela-
noma antigens with species-specific and cross-species reactive 
determinants were studied. 
MATERIALS AND METHODS 
AnimaLs 
C57BL/6 mice, 8- 12 weeks old, were purchased from the Shizuoka 
Experimental Animal Co., Ltd., Hamamatsu, Japan. 
Cell Lines 
P3/X63-Ag8-Ul(P3U1) derived from the BALB/c myeloma cell line 
[6] was obtained from Dr. T. Watanabe, Saga Medical School, Saga, 
Japan. HMV-I human melanoma cell line a nd C57BL/6 mice-derived 
B16 melanoma cells (reviewed in [7]) were kindly supplied by Dr. T . 
Kasuga, Tokyo Medical and Dental University, Tokyo, Japan. Human 
melanoma cell lines (P-36: SK-Mel-28, P -39: MeWo, P-22: SK-Mel-
26) [1,8], which were originally established at the Memorial Sloan-
Kettering Cancer Center, New York, were gifts from Dr. T. Takahashi, 
Aichi Cancer Center, Nagoya, Japan. The cell lines P -36, P -39, P -22, 
and HMV-I were established by primary explant from surgical speci-
mens obtained from four melanoma patients. Methylcholanthrene-
induced A/J sarcoma (S1509a) [9], Rous sarcoma virus (RSV)-induced 
C57BL/IO sarcoma (S913), and benzpyrene-induced C57BL/6 lym-
phoma (EL-4) [10] were kindly supplied by Dr. S. Fujimoto, Kochi 
Medical School, Kochi , Japan. Epstein-Barr virus (EBV)-transformed 
human lymphoblastoid cell line (OKU) was provided by Dr. N. 
Kashiwagi , Kitasato University, Sagamihara, J apan. Human cervix 
carcinoma cell line (Hela -S3) [11] was kindly provided by Dr. T. 
Kuwata, Chiba University, Chiba, Japan. The hamster mela noma cell 
line [12} was a gift from Dr. Y. Mishima, Kobe University, Hyogo, 
Japan. All cell lines were maintained in our laboratory in Dulbecco's 
modified minimal essential medium (D'MEM: Nissui Co., Tokyo, Ja-
pan) supplemented with 5% fetal calf se rum (FCS) . 
Immunization 
816 melanoma cells were treated with 100 /Lg/ ml of mitomycin C 
(MMC: Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) for 45 min at 
37' C. C57BL/6 mice were immunized intraperitoneally with 1 X 10' 
MMC-treated syngeneic 816 melanoma cells at weekly interva ls for 10 
weeks. 
Fu-sion and Cloning 
Three days after the last immunization, cell hybridization was car· 
ried out as described elsewhere [13]. Brie l1 y, 10" primed C57BLj6 
spleen cells were fused with 107 P3U1 myeloma cells in the presence of 
1 ml of prewarmed 50% polyethylene glycol (PEG: MW 1500, Sigma 
Chemical Co., St. Louis, Missouri). Hybridoma cells were se lected bl" 
HAT medium enriched with 10% FCS (HAT medium: RPMI-1 640 
containing 1 X 10- ' M hypoxanthine, 4 X 10- 7 M aminopterin , 1.6 x 
lO- r, M thym idine: Wako Pure Chemica l Industries, Ltd., Osaka, Ja· 
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pan). Culture supernatants of hybrid ce lls grown in HAT mediu~ were 
tested fo r t heir antibody activity on va rIOUS tumor cells. Cells In t he 
pos itive wells were cloned at least twice by limi t ing dilution. 
Cell-Binding Assay 
Target ce lls (5 X 10°) and 50 III of cul ture supernatantsor purified 
monoclonal antibodies were mixed and Incubated for 60 mIn on I.C~ In 
fl ex ible microtlte r p late (Dynatech Labs., Inc., Alexandna, VirgIn ia) . 
~he ce lls were washed, pe lleted, and resuspended in 50 III of 12°!- labeled 
abb it a nt i-mouse immunoglobu lin (Ig) (50,000 cpm/well) , fo llowed by 
: cubation for a furt her 60 min on ice. The cells were extensively 
In 'bl was h ed and dried under heat. The cups of a 96-well flex I e plate were 
cut out, a nd the radioactivity of t he cup was counted by a well -type 
amma counte r (Model Auto AL-201, Dynabot Ltd., Tokyo, Japan). 
~he background was determined by incubating wells with cultu re 
supernata nts of a nt ibodies and radioactive reagents in the absence of 
target cells. 
T reatment of Melanoma Cells with GlycosidaRe 
B 16 mela noma (3 x 107) ce lls were suspended in 3 ml of D'MEM 
ontaining 20 mM Hepes, pH 6.5. They were then reacted with 100 }lg/ 
~l of "mixed" exoglycosidases (Seikagaku Kogyo Co". Ltd., T okyo, 
Japan) conta ining cr- : fj-mannosldase, cr- , fj-glucosldase, cr- , .fj-
galactosidase, cr -L-fucosldase, fj- xylosldase, cr- , fj-N-acetylglucosamIn-
idase, cr - , fj_ N _acetylgalactosaminidase, and 60 III of ~euraminidase (30 
nits Behringwerke AG , Marburg, West Germany) In the presence of 
~ m~ phenylmethylsulfonylfluoride (PMSF: Sigma Chemical Co. , St. 
Louis , Missouri) for.sO mIn at 37°C. After washIng, the cells were 
subjected to cell -bIndIng assay. 
P reparation of"H-Labeled Melanoma A ntigens 
B 16 mela noma cells (1 X 107 ) were cultured for 40 h in 5 ml of the 
leuci ne-free RPM! 1640 medium enriched with 10% dialyzed FCS 
together with 100 IlCi/ ml of ["H]leucine (147 Ci/ mmol, Amersham 
International Ltd. , Amersham, U.K.). The culture supernatants were 
harvested and dia lyzed to remove free radioactive ~ate :ia ls against 
PBS containing 0.1 % NaN, and 2 mM PMSF. The radIOactive mate rIals 
were extensively absorbed with Staphylococcw; au,reus Cowan I (SaCI) 
(500 }ll of the supernata~t per 500 II I of packed SaC I) and centrifuged 
at 6000xg for 10 min. ThiS procedure was repeated tWice. The materIals 
were further reacted with a fresh batch of rabbit anti-mouse Ig-coated 
SaCI to remove nonspecific-binding substances. 
I mmunoprecipitation 
One mill iliter of the cleared radioactive material was mixed with 10 
;tg of purified monoclonal IgM ant i-mel.anoma antibodies (M562 or 
M2590) and incubated on Ice for 60 mIn . Immune complexes were 
absorbed onto goat anti -mouse IgM-coated SaCI (10 III of packed SaC I) 
and incubated for 30 min on ice. The SaCI t hus absorbed was washed 
four times wit h 1.5 ml PBS with careful resuspension of the pellets, 
The materials reacted wit h the antibody-coated SaC I were subse-
quently elu ted with 80 III of sample buffer, 
SDS- Polyacrylamide Gel Electrophoresis 
SDS-PAGE was performed by t he method of Laemmli [14J: 80}l1 of 
the sample was applied to 1.5-mm -thick 10% acrylamide gel with an 
acrylamide to bisacrylamide ratio of 30:0.8. Electrophoresis was per-
formed by 20 rnA of constant current for 5 h. After completion of 
electrophoresis , the gels were frozen, cut in to 2- mm slices, and incu-
bated in 0.3 ml of 90% P rotosol (New England Nuclear Co., Boston, 
Massachusetts) for 12 h at 37°C. The radioactivity was determined 
wit h a liquid scin ti llation counter (LKB-Wallac 1215 Rackbeta, Wal -
lacoy, Turku, Finland). 
Cytotoxic Assay 
A two-step cytotox ic assay was performed as described previously 
[13]. In brief, 4 X 10' ta rget ce lls a nd 20 III of the serially diluted 
antiserum were mixed and incubated for 30 min on ice. T he cells were 
washed and further reacted with rabbit complement for 30 min at 37°C. 
Dead and viable ce lls were counted under a light microscope by trypan 
blue dye exclusion. 
Quantitative Absorption of Monoclonal Antibodies 
Monoclonal M2590 and M562 ant ibodies in t he asc ites of hybridoma-
bearing mice were purified by dia lysis against 10 mM sodium phosphate 
buffer , pH 6.5. The purified antibodies were labeled with 1251Na by the 
methods described elsewhere [1 31: 50 III of 12° I-labeled M2590 or M562 
ant ibody (0.5- 0.1 Ilg/ml) was absorbed wit h graded numbers of tumor 
cell lines of various animal origins or graded amounts of homogenates 
of va rious normal t issues of C57BL/6 mice and tumor mass of B16 
melanoma on ice for 60 min . The residual antibody activity was tested 
on B16 melanoma cells by a cell -binding assay. 
Inhibitioll. of the Antibody Activity with Monosaccharides 
T he purified monoclonal ant ibodies (M2590 or M622) coated on a 
96-well plate were reacted with 50 III (2-200 mM) of monosaccharides 
solut ion (pH 7.2) including o -glucose, o-galactose, o -mannose, L-fu-
cose, N-acetyl-o-galactosamine, N-acetyl-o -glucosamine, N-acetylneu-
raminic acid, or o -xylose followed by incubating with 15 III of B16 
culture supernate on ice fo r 1 h. They were t hen washed and further 
reacted with 50 III of the l" l -labeled M2590 antibody (70,000 cpm/ well ) 
on ice for 1 h. The radioactivity of t he cup was counted by a well -type 
gamma counter (Dynabot Ltd., Tokyo, J apan) , 
Treatment with Tunicamycin 
Mouse melanoma cells (3 x lOG/ ml) were cultured for 72 h in RPM I-
1640 containing 4% FCS and 0.5 }lg/ ml of tun icamycin (Sigma Chem-
ical Co" St. Louis, Missouri). The melanoma cells t hus cultured were 
tested for their expression of the cross-species melanoma antigens by 
using cell -binding assay. 
RESULTS 
Detection of Interspecies Cross-Reactive Determinants on the 
Mammalian Melanoma Cells 
To investigate interspecies cross- reactive melanoma deter-
mina n ts at t he antibody level, t he a ntisera raised in C57BL/6 
mice repeatedly immunized t he syngene ic B16 melanoma were 
tested for activ ity on various melanoma cells. About 10% of 
the mice immunized produced antibodies cross- reacting with 
mouse, hamster, and human m e la n oma cells. The typical results 
are s hown in Fig 1. The a n t iserum (C57BL/6 a nti -B16 m ela-
noma) killed m o re than 90% of B16 melanoma a nd 40- 50% of 
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FIG 1. Cytotox ic curves of C57BL/ 6 anti-B16 melanoma antiserum. 
The cytotoxic assay was performed by t he two-step dye exclusion 
cytotox ic test as described in Maten:als and Methods , Target cells; B16 
melanoma (C57BL/ 6) (e) , hamster melanoma (0), human melanoma 
(P-39) (x), EL-4 lymphoma (C57BL/6) (6) or human cervix carcinoma 
(Hela-S3) (A) . The background in the experiments was less than 10%. 
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hamster and human melanoma cells, while no cytotoxic activity 
was observed on C57BL/6-derived T-lymphoma (EL-4) or hu -
man carcinoma (Hela-S3) . 
Syngeneic Monoclonal Antibodies against Melanoma Antigens 
The somatic cell hybridization was carried out to obtain 
monoclonal antibodies specific for melanoma antigens. So far , 
two types of hybrids producing monoclonal antibodies (desig-
nated as M2590 and M622 or M562) have been establi shed. 
These antibodies were determined to be serologically IgM. 
Table I shows the speci fi e binding activity of the monoclonal 
antibodies. The M562 antibody reacted exclusively with B16 
melanoma cells, but not with other tumor cell lines of mouse 
and human origin nor hamster and human melanomas. The 
same specific ity as that of the M562 antibody was observed on 
the M622 antibody. However, the M2590 antibody reacted with 
human and hamster melanoma cells as well as mouse melanoma 
cells, but not with other non melanoma cell lines of mouse and 
human origin. The only exceptional case observed was that the 
M2590 antibody could not react with one of the four human 
melanoma cell lines (P-22). 
The cross-species reactivity and the specificity of the mono-
clonal antibodies were further confirmed by a quantitative 
absorption assay. As shown in Fig 2, the antibody activity of 
M2590 was absorbed with melanoma cell lines of human (P-
39), hamster, and mouse (B16) origin, while other nonmela-
noma tumor cell lines had no detectable absorbing capacity. 
Therefore, t he results confirmed the interspecies cross-reactiv-
ity of the M2590 antibody shown in Table 1. 
The tumor reactivity of the monoclonal antibodies is shown 
in F ig 3. The activity of the M2590 antibody was completely 
abrogated by absorption with B16 melanoma, whereas no ab-
sorption was observed by the homogenates of normal tissues, 
including eye, brain, and skin, which should contain normal 
melanocytes. A similar result was obtained by using the M562 
and M622 antibodies. Thus it is strongly suggested t hat the 
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FIG 2. Quantitative absorption analysis of the monoclonal anti-
melanoma (M2590) antibody with various tumor cell lines. '·"I-Iabeled 
purified M2590 antibody (50 pI) was absorbed with graded numbers of 
tumor cell li nes, such as human melanoma (P-39) (6), hamster mela -
noma (.), mouse melanoma (B16) (.), human neuroblastoma (NB-
GOTO) (0), human carcinoma (Hela-S3) (X), mouse neuroblastoma 
(C1300) ('&), or mouse lymphoma (EL-4) (0). The residual binding 
activity of the M2590 antibody was assayed on B16 melanoma cells by 
ce ll -binding assay. 
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TABLE l. Reactivity of monoclonol anti-mouse mehmoma antibodies · 
Origin 
Cell -binding activity (cpm) of: 
Target cell lines 
M562 M2590 
B16 melanoma C57BL/6 4659 ± 46 b 3206 ± 97 
EL-4 lymphoma C57BL/6 41 ± 11 115 ± 49 
S913 sarcoma C57BL/ IO 41 ± 23 78 ± 23 
S1590a sarcoma A/J 63 ± 17 101 ± 28 
C1300 neuroblastoma A/J 28 ± 11 89 ± 16 
P3Ul.myelomll BALB/c 51 ± 20 93 ± 12 
P -36 melanoma Human 39 ± 25 757 ± 27 
P -39 melanoma Human 50 ± 8 1656 ± 64 
HMV-I melanoma Human 71 ± 18 570 ± 33 
P-22 melanoma Human 29 ± 21 120 ± 27 
OKU B-cell blast Human 27 ± 12 60 ± 14 
Hela-S3 carcinoma Human 30 ± 14 78 ± 8 
NB-GOTO neuro- Human 21 ± 11 109 ± 30 
blastoma 
NB-I neuroblastoma Human 82 ± 16 83 ± 20 
Normal lymphocytes Human 40 ± 22 90 ± 11 
Hamster melanoma Hamster 163 ± 28 1401 ± 44 
a Cultured tumor cell lines or EBV -transformed cell lines of human, 
mouse, or hamster origin (5 X 10") were reacted with 50 pI of hybridoma 
supernates containing monoclonal antibodies (M562 or M2590) on ice 
for 60 min followed by reacting with ' 2['I-labeled rabbit anti-MIg. 
b The numbers indicate the arithmetic means of counts (cpm) of 4 
individuals ± SD. 
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FIG 3. Quantitative absorption a nalysis of t he monoclonal anti -
melanoma (M2590) antibody with tissue homogenates. ""I-labeled pur-
ified M2590 antibody (50 pI of 0.5 pg/ml) was absorbed with twofold 
dilution of the following tissue homogenates of C57BL/6 mice: spleen 
(.), lung ('&), liver (0), thyroid (6), brain (0), kidney (X), skin (\7) , 
eye (.), and tumor mass of B16 melanoma (-'). The residual binding 
activity of the M2590 antibody thus absorbed was assayed on B16 
melanoma cells. Similar results were also obtained with the M562 or 
M622 antibody. 
monoclonal antibodies (M562 or M622 and M2590) recognize 
antigenic determinants expressed on and unique to the mela-
noma cells. Furthermore, the M562 and M622 antibodies were 
shown to react with the determinant expressed only on mouse 
(BI6) melanoma cells, whereas the M2590 determinant was 
found to be shared at least among mouse, hamster, and human 
melanoma cells. 
Interspecies Cross-Reactive Melanoma Antigens with 
Sugar Moiety 
In order to characterize properties of the melanoma antigens, 
B16 melanoma cells were treated with a mixture of exoglyco-
sidases. Target cells with or without treatment were reacted 
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TABLE II. Effects of exoglycosidases on the expression of species-
specific and interspecies cross-reactive melanoma antigenic 
determinants" 
Monoclonal 
a n t ibOdy 
M562 
M2590 
M2590 
M2590 
Target ce lls 
C57B L/6 melanoma 
C57BL/6 melanoma 
Human melanoma 
Hamster melanoma 
Bi ndin g activity (cpm) on target 
ce lls treated with: 
No ne Glycosidases 
11 26±9" 
24 13±80 
1086 ± 75 
413 ± 12 
1366 ± 93 
77 ± 11 
97 ± 13 
106 ± 10 
a Melanoma cells of mouse, hamster, or human origin (5 X 10' ) 
retreated with or without the mixture of exoglycosidases were reacted ~ith 50 III of monoclonal antibodies (M562 or M2590) at a concentra-
t io n of 5 Ilg/m l fono~ed by reacting with '""l-labeled rabbit anti -MIg. 
b The numbers lIldlcate the anthmetlc means of counts (cpm) of 4 
individuals ± SO. 
TABLE III. Effect of tunicamycin on the expression of the cross-species 
melanoma antigen 
Drug treatment" 
Before 
During 
After 
Binding activity (cp m) 
3261 ± 198" 
413 ± 13 
2937 ± 146 
a B16 melanoma cells (3 x 10G/ml) were cultured for 72 h in the 
presence of 0.5 Ilg/ ml of tunicamycin. The cells were subsequently 
cu ltured for 180 h in the absence of the drug. The melanoma cens thus 
t reated were tested for their expression of cross-species melanoma 
antige ns by cell -binding assay with the I·" l ·labeled M2590 antibody. 
b The numbers indIcate the anthmetlc means of counts (cpm) of 4 
individuals ± SO. 
with the M562 or the M2590 antibody. The binding of the 
M562 antibody was not affected by the treatment, whereas no 
binding of the M2590 antibody was observed after the treat-
ment. Similar results were obtained with the M2590 antibody 
when the human and hamster melanoma cells treated with 
exoglycosidases were used as ta:get cells. (Table II). These 
results indicate that the sugar mOiety constitutes the mterspe-
cies cross-reactive epitope defined by M2590, whereas this is 
probably not the case with the determinant detected by the 
M562 antibody. 
The carbohydrate nature of the M2590 determinant was 
investigated by the tun icamycin treatment. The results shown 
in Table III demonstrated that the reactivity of the M2590 
antibody was abrogated after t reatment with tunicamycin and 
recovered after release of the drug treatment, indicating that 
the N-asparagine-linked glycosylation process seems to be in-
volved in the formation of the interspecies cross-reactive deter-
minant. 
The sugar moiety of the cross-species determinant was also 
confirmed by the inhibition of the M2590 antibody with mono-
saccharides. As shown in Fig 4, the binding activity of the 
M2590 antibody to the melanoma antigen was inhibited by 
high doses (50-200 mM) of monosaccharides (i.e., D-glucose, D-
galactose, D-mannose, L-fucose, N-acetyl-D-galactosamine, N-
acetyl-D-glucosamine, and N-acetyl-neuraminic acid). How-
ever, the same treatment did not affect the reactivity of the 
M622 antibody. Based on the preceding results, the mouse 
melanoma-specific determinants recognized by the M622 anti-
body seem to be proteinaceous in nature. However, the M 2590 
antibody recognize the interspecies cross-reactive determinants 
composed of sugar moiety. 
Interspecies Cross-Reactive and Species-Specific Melanoma 
Antigenic Determinants Expressed on the Same Molecule 
The physicochemical properties of the melanoma antigen 
were analyzed on SDS-PAGE. Fig 5A and B show the SDS-
PAGE profiles of the melanoma antigens precipitated with the 
M562 and M2590 antibodies, respectively. The M562 antibody 
precipitated one major peak having a molecular weight of 31,000 
and two minor peaks (46,000 and 70,000). S imila rly, t he M2590 
antibody with cross-spec ies specificity precipitated one major 
peak having molecular weight of 31,000 and small peaks having 
molecular weights of 46,000 and 70,000. There was no precipi-
tat ion, however, with IgM myeloma protein used as a control 
(Fig 5C). Therefore, t he major protein peaks precipitated by 
t he M562 and M2590 antibodies were found to have the same 
molecular weight of 31,000. 
In order to determine whether t he species-specific and in ter-
species cross-reactive determinants are present on the same 
molecule, t he sequential precipitation ana lysis was carried out 
using the M562 and M2590 antibodies. The cul ture supernatant 
c~ntaining [3H)leucine-Iabeled melanoma antigens was reacted 
With the excess amount of t he first antibody (either of the 
M2590 or M562 an tibody). The resultant precipitates were 
removed, and the supernatant was subsequently reacted with 
the second antibody with reciprocal combinations. As shown in 
Fig 5D-F, t here was no precipitation by the second antibodies 
from the supernatants precleared by the first an t ibody, whereas 
the materials with a molecular weight of 31,000 were precipi-
tated by either t he M2590 or M562 antibody from t he super-
natant prereacted with control HPC-76 myeloma protein 
(IgM) . The M622 antibody was also shown to react with the 
31,000 molecule. Thus it is concluded that the two distinct 
melanoma antigenic determinants, i.e. , the species-specific and 
the interspecies cross-reactive determinants, are present on the 
same molecule. 
DISCUSSION 
Melanoma is one of t he malignant tumors t hat has been 
shown to express antigens unique to and shared by tumor cells 
of common histologic origin. In t his respect, Carey et a l and 
Shiku et al have found, in sera of melanoma patients, antibodies 
specifically reactive not only with the autochthonous tumor 
cells, but a lso with other human melanoma cell lines derived 
from different patients [1 - 4). Recently, we have extended the 
observation to an animal model and have demonstrated the 
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FIG 4. Inhibitory effect of monosaccharides on the reactivity of the 
M2590 antibody. The M2590 (e) or M622 (0) antibody coated on a 
96-well plastic plate was preincubated for 5 h with 50 III of various 
concentrations of monosaccharides, such as D-glucose (Glc), D-galac-
tose (Gal), D-mannose (Man), D-xylose (Xyl) , L-fucose (Fuc), N-acetyl-
D-glucosamine (GlcNAc), N-acetyl-D-galactosamine (GalNAc) , and N-
acytylneuraminic acid (NANA). The mixture was further reacted for 1 
h with 15 III of B16 melanoma culture supernates. The plates were 
extensively washed and further reacted for 1 h with mI-labeled M2590 
antibody. The assay was carried out on ice. Percent binding of the 
activity of the M2590 antibody was calculated by the following formula: 
P b· d" with inhibi tor (cpm) ercent 111 Ing = X 100 
without inhibitor (cpm) 
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FIG 5. Sequential precipitation of melanoma antigens with mono-
clonal antibodies. ["HJLeucine-labeled melanoma antigens were reacted 
with 10 p.g of the purified M562 (lgM) (A), M2590 (lgM) (B) antibody, 
or myeloma protein (HPC-76: IgM) (C). The immune complexes were 
precipitated by reacting with SaCI-coated goat anti-mouse IgM. The 
supernates were further reacted with 10 p.g of the M2590 (D) or M562 
(E, F) antibody in the reciprocal combinations. The precipitates were 
analyzed on SDS-PAGE (10% gels). Note that the peak at 31,000 
daltons was obtained by either the M562 or M2590 antibody in the 
primary precipitation, whereas nothing was obtained in the secondary 
precipitation. Molecular weight markers used are phosphorylase B (94 
K), bovine serum albumin (68 K), ovalbumin (45 K) , carbonic anhy-
drase (30 K), soybean trypsin inhibitor (21 K), and lysozyme (14.3 K) . 
NP-40 extracts or the culture supernates from "H-Iabeled melanoma 
cells gave the same results. The data shown here a re obtained by using 
the culture supernates. 
existence of the interspecies cross-reactive antigenic determi-
nants on human and mouse melanoma cells detected by murine 
cytotoxic T-Iymphocytes specific for syngeneic melanoma cells 
[5] . These observations have also indicated that the host im-
mune system is capable of recognizing and responding to such 
tumor-associated antigenic determinants. To study the prop-
erties of melanoma antigen is, therefore, of obvious significance. 
In order to elucidate the immunologic and biochemical char-
acteristics of such tumor antigens, two types of hybridoma cell 
lines producing antibodies specific for melanoma antigens were 
successfully established by the syngeneic immunization (Table 
1). The M562 or the M622 antibody defines the mouse mela-
noma (B16 melanoma)-specific determinants. However, the 
M2590 antibody recognizes the interspecies cross-reactive de-
terminant on melanoma cells shared at least among mouse, 
hamster, and human. The cross-species reactivity of the M2590 
antibody was also confirmed by the quantitative absorption 
with tumor cell lines of various animal origins (Fig 2) . Further-
more, these monoclonal antibodies were found to be specific 
for melanoma cells, since the antibody activity was not ab-
sorbed with normal tissues or organs (Fig 3). 
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The existence of common neuroectodermal antigenic deter-
minants expressed on human melanoma, neuroblastoma, glio-
blastoma, and fetal brain has been demonstrated by using 
mouse monoclonal antibodies against human melanoma cells 
[15] . However, this is not the case with the melanoma antigen 
described here, since our monoclonal antibodies could not react 
with several neuroblastomas of mouse and human origin (Table 
I and Fig 2). 
The amounts of the cross-species determinants expressed on 
the cell surface were found to be different from each melanoma 
cell line. The human (P-39) and mouse (BI6) melanoma cells 
express the M2590 determinants about 10 times as much as do 
the hamster melanoma cells (Fig 2). This was also true among 
human melanoma lines. The M2590 antibody failed to react 
with one of the four different human melanoma cells (P-22) 
(Table 1). However, sandwich radioimmunoassay using the 
antibody recently established in our laboratory detected the 
melanoma antigens from P-22 cells [16], suggesting that the P-
22 melanoma does express cross-reactive antigens hardly de-
tected by the cell-binding assay. Therefore, this suggests the 
heterogeneous expression of cross-species antigenic determi-
nants on individual melanoma cell lines. 
The immunochemical and physicochemical analyses have 
shown that the antigen defined by the M2590 antibody has the 
same molecular weight (31,000) as that detected by the M562 
or t.he M622 antibody. Furthermore, the sequential precipita-
tion analyses shown in Fig 5 clearly demonstrated that the 
mouse-specific and the interspecies cross-reactive melanoma 
antigenic determinants are on the same molecule. 
The mouse melanoma-specific determinants recognized by 
the M562 or the M622 antibody seemed to be proteinaceous in 
nature. However, the cross-species determinants were found to 
be composed of sugar moiety (Table II) . Moreover, the terminal 
sialic acid of the carbohydrate side chain has been found to be 
crucial for the expression of the interspecies cross-reactive 
determinant, since treatment with neuraminidase alone was 
sufficient to destroy the cross-species determinant and the same 
treatment preserved the M562 determinant [17]. 
The sugar moiety of the cross-species melanoma antigen was 
also confirmed by the following two experiments. First, B16 
melanoma cells completely lost their expression of the cross-
species determinant after treatment with tunicamycin (Table 
Ill). Second, the reactivity of the M2590 antibody onto the 
melanoma antigen was greatly inhibited by high doses of 
monosaccharides (Fig 4). These results strongly suggest that 
the cross-species melanoma antigenic determinant is composed 
of the carbohydrate side chain. 
The biological significance of the cross-reactive melanoma 
antigens with carbohydrate moiety is unknown. However, we 
can speculate on its involvement in the state of malignancy, 
since the determinants were not detected on normal melano-
cytes. In this sense, a specific glycosylation may show the 
increased activity and may appear in transformed cells as 
reported by Buck et al [18] and Warren et al [19]. They have 
described that increased amounts of specific glycosyl transfer-
ase were found in virus-transformed cells rather than in normal 
cells. Moreover, Ogata et al [20] and Takasaki et al [21] have 
also demonstrated that transformed cells were relatively rich 
in oligosaccharides with profusely branched outer chains when 
compared with normal cells. It is, however, possible that an 
oncogenic virus infection may be responsible for expression of 
the cross-reactive determinants commonly shared among mam-
malian melanoma cells. If this is the case, abnormal glycosyla-
t ion may be related to the structure of the glycoprotein that 
composes the melanoma antigens controlled by oncogenic 
viruses. 
Further biochemical characterizations of the melanoma an-
tigens from various mammalian species by using the mono-
clonal antibody with cross-spec ies reactivity (M2590) would 
provide a definite answer to these assumptions. 
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